Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Preanalytical considerations in the design of clinical trials and epidemiological studies.

Kellogg MD, Ellervik C, Morrow D, Hsing A, Stein E, Sethi AA.

Clin Chem. 2015 Jun;61(6):797-803. doi: 10.1373/clinchem.2014.226118. Epub 2015 Apr 21. No abstract available.

2.

In reply.

Cole TG, Contois JH, Csako G, McConnell JP, Remaley AT, Devaraj S, Hoefner DM, Mallory T, Sethi AA, Warnick GR.

Clin Chem. 2013 Aug;59(8):1277-8. No abstract available.

3.

Association of apolipoprotein B and nuclear magnetic resonance spectroscopy-derived LDL particle number with outcomes in 25 clinical studies: assessment by the AACC Lipoprotein and Vascular Diseases Division Working Group on Best Practices.

AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices, Cole TG, Contois JH, Csako G, McConnell JP, Remaley AT, Devaraj S, Hoefner DM, Mallory T, Sethi AA, Warnick GR.

Clin Chem. 2013 May;59(5):752-70. doi: 10.1373/clinchem.2012.196733. Epub 2013 Feb 5. Erratum in: Clin Chem. 2013 Aug;59(8):1275.

4.

High-density lipoprotein cholesterol efflux, nitration of apolipoprotein A-I, and endothelial function in obese women.

Vazquez E, Sethi AA, Freeman L, Zalos G, Chaudhry H, Haser E, Aicher BO, Aponte A, Gucek M, Kato GJ, Waclawiw MA, Remaley AT, Cannon RO 3rd.

Am J Cardiol. 2012 Feb 15;109(4):527-32. doi: 10.1016/j.amjcard.2011.10.008. Epub 2011 Nov 19.

5.

β2-adrenergic receptor polymorphisms, asthma and COPD: two large population-based studies.

Thomsen M, Nordestgaard BG, Sethi AA, Tybjærg-Hansen A, Dahl M.

Eur Respir J. 2012 Mar;39(3):558-66. doi: 10.1183/09031936.00023511. Epub 2011 Nov 10.

6.

Genetic variation in liver X receptor alpha and risk of ischemic vascular disease in the general population.

Stender S, Frikke-Schmidt R, Anestis A, Kardassis D, Sethi AA, Nordestgaard BG, Tybjærg-Hansen A.

Arterioscler Thromb Vasc Biol. 2011 Dec;31(12):2990-6. doi: 10.1161/ATVBAHA.111.223867. Epub 2011 Sep 8.

PMID:
21903943
7.

S1P, dihydro-S1P and C24:1-ceramide levels in the HDL-containing fraction of serum inversely correlate with occurrence of ischemic heart disease.

Argraves KM, Sethi AA, Gazzolo PJ, Wilkerson BA, Remaley AT, Tybjaerg-Hansen A, Nordestgaard BG, Yeatts SD, Nicholas KS, Barth JL, Argraves WS.

Lipids Health Dis. 2011 May 9;10:70. doi: 10.1186/1476-511X-10-70.

8.

High pre-beta1 HDL concentrations and low lecithin: cholesterol acyltransferase activities are strong positive risk markers for ischemic heart disease and independent of HDL-cholesterol.

Sethi AA, Sampson M, Warnick R, Muniz N, Vaisman B, Nordestgaard BG, Tybjaerg-Hansen A, Remaley AT.

Clin Chem. 2010 Jul;56(7):1128-37. doi: 10.1373/clinchem.2009.139931. Epub 2010 May 28.

9.

Structure/function relationships of apolipoprotein a-I mimetic peptides: implications for antiatherogenic activities of high-density lipoprotein.

D'Souza W, Stonik JA, Murphy A, Demosky SJ, Sethi AA, Moore XL, Chin-Dusting J, Remaley AT, Sviridov D.

Circ Res. 2010 Jul 23;107(2):217-27. doi: 10.1161/CIRCRESAHA.110.216507. Epub 2010 May 27.

10.

Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the LIFE study.

Nordestgaard BG, Kontula K, Benn M, Dahlöf B, de Faire U, Edelman JM, Eliasson E, Fyhrquist F, Hille DA, Ibsen H, Lyle PA, Berg K, Sandberg M, Sethi AA, Wong PH, Os I.

Pharmacogenet Genomics. 2010 Feb;20(2):77-85. doi: 10.1097/FPC.0b013e328333f70b.

PMID:
20065889
11.

Lecithin: cholesterol acyltransferase--from biochemistry to role in cardiovascular disease.

Rousset X, Vaisman B, Amar M, Sethi AA, Remaley AT.

Curr Opin Endocrinol Diabetes Obes. 2009 Apr;16(2):163-71. Review.

12.

Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices.

Contois JH, McConnell JP, Sethi AA, Csako G, Devaraj S, Hoefner DM, Warnick GR; AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices.

Clin Chem. 2009 Mar;55(3):407-19. doi: 10.1373/clinchem.2008.118356. Epub 2009 Jan 23.

13.

Asymmetry in the lipid affinity of bihelical amphipathic peptides. A structural determinant for the specificity of ABCA1-dependent cholesterol efflux by peptides.

Sethi AA, Stonik JA, Thomas F, Demosky SJ, Amar M, Neufeld E, Brewer HB, Davidson WS, D'Souza W, Sviridov D, Remaley AT.

J Biol Chem. 2008 Nov 21;283(47):32273-82. doi: 10.1074/jbc.M804461200. Epub 2008 Sep 19.

14.

Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease.

Frikke-Schmidt R, Nordestgaard BG, Stene MC, Sethi AA, Remaley AT, Schnohr P, Grande P, Tybjaerg-Hansen A.

JAMA. 2008 Jun 4;299(21):2524-32. doi: 10.1001/jama.299.21.2524.

PMID:
18523221
15.

Angiotensinogen and ACE gene polymorphisms and risk of atrial fibrillation in the general population.

Ravn LS, Benn M, Nordestgaard BG, Sethi AA, Agerholm-Larsen B, Jensen GB, Tybjaerg-Hansen A.

Pharmacogenet Genomics. 2008 Jun;18(6):525-33. doi: 10.1097/FPC.0b013e3282fce3bd.

PMID:
18496132
16.

Genetic variation and activity of the renin-angiotensin system and severe hypoglycemia in type 1 diabetes.

Pedersen-Bjergaard U, Dhamrait SS, Sethi AA, Frandsen E, Nordestgaard BG, Montgomery HE, Pramming S, Hougaard P, Thorsteinsson B.

Am J Med. 2008 Mar;121(3):246.e1-8. doi: 10.1016/j.amjmed.2007.12.002.

PMID:
18328310
17.

Apolipoprotein AI mimetic peptides: possible new agents for the treatment of atherosclerosis.

Sethi AA, Amar M, Shamburek RD, Remaley AT.

Curr Opin Investig Drugs. 2007 Mar;8(3):201-12. Review.

PMID:
17408115
18.

164Ile allele in the beta2-Adrenergic receptor gene is associated with risk of elevated blood pressure in women. The Copenhagen City Heart Study.

Sethi AA, Tybjaerg-Hansen A, Jensen GB, Nordestgaard BG.

Pharmacogenet Genomics. 2005 Sep;15(9):633-45.

PMID:
16041242
19.

Nanogen microelectronic chip for large-scale genotyping.

Sethi AA, Tybjaerg-Hansen A, Andersen RV, Nordestgaard BG.

Clin Chem. 2004 Feb;50(2):443-6. No abstract available.

20.

Angiotensinogen gene polymorphism, plasma angiotensinogen, and risk of hypertension and ischemic heart disease: a meta-analysis.

Sethi AA, Nordestgaard BG, Tybjaerg-Hansen A.

Arterioscler Thromb Vasc Biol. 2003 Jul 1;23(7):1269-75. Epub 2003 Jun 12.

PMID:
12805070
21.

Angiotensinogen single nucleotide polymorphisms, elevated blood pressure, and risk of cardiovascular disease.

Sethi AA, Nordestgaard BG, Grønholdt ML, Steffensen R, Jensen G, Tybjaerg-Hansen A.

Hypertension. 2003 Jun;41(6):1202-11. Epub 2003 May 12.

PMID:
12743009
22.

[Six case-control studies from the Osterbro-study (The Copenhagen City Heart Study). Angiotensinogen mutations and risk of myocardial and cerebral ischemia].

Sethi AA, Tybjaerg-Hansen A, Grønhold ML, Steffensen R, Schnohr P, Nordestgaard BG.

Lakartidningen. 2002 May 23;99(21):2392-3. Swedish. No abstract available.

PMID:
12090166
23.

Angiotensinogen mutations and risk for ischemic heart disease, myocardial infarction, and ischemic cerebrovascular disease. Six case-control studies from the Copenhagen City Heart Study.

Sethi AA, Tybjaerg-Hansen A, Grønholdt ML, Steffensen R, Schnohr P, Nordestgaard BG.

Ann Intern Med. 2001 May 15;134(10):941-54.

PMID:
11352695
24.

Angiotensinogen polymorphisms and elevated blood pressure in the general population: the Copenhagen City Heart Study.

Sethi AA, Nordestgaard BG, Agerholm-Larsen B, Frandsen E, Jensen G, Tybjaerg-Hansen A.

Hypertension. 2001 Mar;37(3):875-81.

PMID:
11244011

Supplemental Content

Loading ...
Support Center